SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ZoraAI agents are designed to take the complexity out of everyday tasks, leaving you with more time and energy to focus on what matters most. With their powerful automation and adaptability, your life and work will become more efficient and effortless. With ZoraAI, you’re in control. The customizable agents feature lets you mix and match your favorite tools and capabilities from different agents to build one that’s perfectly tailored to your needs. Whether you want a multitasking powerhouse or a focused specialist, your personalized agent is designed to work exactly how you want it to—no coding required.

Zoracles

Zoracles (ZORA.X) is trending amidst volatile price action and heavy community debate regarding its potential. Some traders cite bullish setups and high volume as reasons for optimism, while others express concerns about repeated rejections at certain price levels and its overall long-term viability. The discussions also highlight its recent listing on Coinbase and the integration of tokenized posts within the Base App.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X, a memecoin on the Bitcoin blockchain launched via the Runes protocol, is trending as the community rallies around its fair launch and potential to drive Bitcoin's cultural and economic relevance. Many believe $DOG.X could be the next big memecoin, drawing comparisons to $DOGE.X, while others highlight its unique position within the Bitcoin ecosystem and its potential for significant growth.

WorldFinancial

WorldFinancial (WLFI.X) is trending amidst community discussions about its potential and recent price volatility. Some traders are pointing to a task force and account freezes while others are speculating on future value based on reserves. Concerns around key figures like Justin Sun and his involvement are also being heavily discussed.

What is Tron? Tron's mission is to build a truly decentralized internet and aims to be the largest blockchain-based operating system in the world, known as the TRON protocol. The TRON protocol will offer high scalability, high availability, and high throughput computing to serve decentralized applications via smart contracts. Ethereum EVM-based smart contracts will be compatible and deployable on the TRON network as such Solidity developers do not have to rewrite their applications.  Why Tron? Since TRON protocol does not rely on proof of work or mining, instead governed by nodes located around the world, it is decentralized while providing high throughput for transactions on the blockchain. This is suitable for dapps that require high speed transactions especially games. There are a number of tokens already issued on the TRON network and the decentralized exchanges TRX.market has launched.  On July 24th 2018, TRON acquired BitTorrent, one of the largest P2P file sharing protocol. As a result of the acquisition, BitTorrent Token (BTT) was launched as the cryptocurrency to power the economics on the BitTorrent network. The Token will be used to inceltivize file sharing and storage within the network.

Tron

Tron is trending as discussions revolve around its potential Nasdaq listing via a reverse merger and its strong position in stablecoin transactions, particularly USDT. Community members are also discussing Tron's relationship with Rumble, including cloud deals and Tether's stake in the platform, with some comparing Tron to other blockchains like Keeta.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending due to its connection to Bitcoin Runes and recent airdrops, creating a strong community.  The community is excited about potential tier 1 exchange listings and its potential to become a leading memecoin in the Bitcoin ecosystem.  Some are also discussing the relationship between $DOG and $CBLO, with $CBLO increasing its treasury holdings in $DOG.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond (BBBY) is trending as traders discuss its corporate rebranding from BYON, potential short squeeze, and possible connections to blockchain technology through Tzero. The community is also speculating about the influence of Marcus Lemonis and comparing BBBY's situation to the GameStop ($GME) saga. Discussions include whether the ticker change represents a fresh start or a continuation of past challenges.

Space and Time is the Microsoft-backed blockchain for ZK-proven data. Powered by Proof of SQL, a sub-second ZK coprocessor, Space and Time allows smart contracts, AI agents, and onchain applications to query onchain and offchain data at scale and verify the results with cryptographic proofs. The foundation of Space and Time is a decentralized layer 1 blockchain where validators verify every piece of data that gets inserted into the network, updating and signing cryptographic commitments on the data before recording them onchain. Developers can query this data via Proof of SQL and receive back a trustless, tamperproof result onchain. Space and Time allows smart contracts to query over the full history of major blockchains and offchain sources in a verifiable way, enabling a new generation of sophisticated, data-driven onchain apps.  The SXT token is deployed as an ERC-20 token on Ethereum and functions as the network's native utility token. SXT is used for staking, data processing payments, access control, and incentives for data contributors.

Space and Time

Space and Time ($SXT.X) is trending as the community discusses its recent listing and staking opportunities, while also pointing to its potential given the project's ties to Microsoft and Samsung. Many believe SXT is currently undervalued, emphasizing its unique approach to verifiable data warehousing. The conversation also highlights the long-term potential and accumulation strategies, with some suggesting it's an early entry point before wider recognition.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

Traders are watching GYRO, a low float stock, for potential parabolic movement and a possible short squeeze, with some drawing comparisons to other recent low float runners. A recent land sale boosting NAV is attracting attention, and the community is discussing key breakout levels and potential price targets, anticipating a significant move if volume increases. The company's liquidation plan and potential for unlocking shareholder value are also part of the conversation.

Rbb Fund Inc - SGI Enhanced Core ETF

SGI Enhanced Core ETF

The SGI Enhanced Core ETF ($USDX) is trending as traders analyze its potential downside, with many pointing to momentum hinting at a downside extension based on Elliott Wave analysis. Community discussions revolve around high-frequency trading patterns and key levels for potential reactions. Traders are watching the index closely, especially ahead of the NFP data, for signals on its future direction within the broader forex market.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending amid speculation of a potential BlackRock ETF filing, with the community actively discussing its implications. Many community members are expressing excitement about the possibility of institutional investment and the potential for HBAR to become a leading cryptocurrency. Additionally, Hedera's underlying technology and real-world use cases continue to be a central point of discussion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioNTech SE (BNTX) announced on Friday that a late-stage trial, conducted by its partner Duality Biologics in China, has met its primary endpoint of progression-free survival at a pre-specified interim analysis. The trial is evaluating Trastuzumab Pamirtecan versus Trastuzumab Emtansine in patients with certain types of breast cancer.Shares of the company traded 10% higher in the pre-market session on Friday. The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biontech.de/news-releases/news-release-details/biontech-and-dualitybio-announce-phase-3-trial-adc-candidate">trial</a> enrolled 228 patients with HER2-positive unresectable or metastatic breast cancer, an aggressive form of the disease that has spread and cannot be surgically removed, who previously received Trastuzumab and a taxane-based chemotherapy.On Stocktwits, retail sentiment around BNTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_8_57_36_AM_png_5a9988a80e.webp" alt="BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure> DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.DualityBio Global Medical Officer Hua Mu noted that breast cancer has a high incidence rate in China, with over 350,000 new cases annually.“Together with our partner BioNTech, we plan the development of Trastuzumab Pamirtecan in further tumor types towards BLA application in other regions including the United States and the European Union to maximize its potential for patients around the world,” Mu said.BioNTech also noted that this is the first positive late-stage data readout achieved in the collaboration between the two companies initiated in April 2023. The collaboration aims to accelerate the development of differentiated antibody drug-conjugate therapeutics for solid tumors.BioNTech holds global commercial rights for Trastuzumab Pamirtecan, while DualityBio has commercial rights for Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.BNTX stock is down by 9% this year but up by about 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-proposes-whopping-1-trillion-pay-package-for-ceo-elon-musk/chwIJkaRdpr">Tesla Proposes Whopping $1 Trillion Pay Package For CEO Elon Musk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

Why Did BioNTech Stock Surge 10% Pre-Market Today?

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.

Equity

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.


Pfizer Inc. (PFE) and BioNTech SE (BNTX) said on Wednesday that the U.S. Food and Drug Administration has approved the application of its LP.8.1-adapted monovalent COVID-19 vaccine for use in senior adults as well as in younger individuals who are at risk of severe outcomes from the infection.The agency approved the vaccine for use in adults aged 65 years and older, as well as in individuals aged 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.The companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontechs-comirnatyr-receives-us-fda-approval">said</a> that the approval is based on a body of evidence supporting the safety and efficacy of the vaccine, including clinical trial data supporting approval for children 5 through 11 years of age.On Stocktwits, retail sentiment around PFE trended within ‘neutral’ territory over the past 24 hours while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:622/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_2_09_36_PM_png_c697ca4665.webp" alt="PFE's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 27, 2025 | Source: Stocktwits" width="622" height="60"><figcaption>PFE's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around BNTX stayed within ‘bullish’ territory, accompanied by ‘high’ levels of retail chatter.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_2_10_26_PM_png_722e599af9.webp" alt="Screenshot 2025-08-27 at 2.10.26 PM.png"><figcaption>BNTX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance, the companies said. The companies added that the vaccine will begin shipping immediately and be available in pharmacies, hospitals, and clinics across the U.S. in the coming days.Earlier in the day, U.S. Health Secretary Robert F. Kennedy Jr. <a href="https://stocktwits.com/news-articles/markets/equity/robert-kennedy-jr-announces-end-of-fda-covid-mandates/chsUJ4VRdla">stated</a> in a post on X that the FDA has now granted full marketing authorization for certain COVID-19 vaccines targeting higher-risk groups. Moderna’s (MRNA) shot has been authorized for individuals six months and older, Pfizer's (PFE) for ages five and up, and Novavax's (NVAX) for ages 12 and above, all of whom are at higher risk, he said.“The American people demanded science, safety, and common sense,” Kennedy said.Moderna <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6729249760870595&amp;symbol=MRNA">confirmed</a> the news and said that the FDA has approved its 2025-2026 formulas for Spikevax and mNEXSPIKE, targeting the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The updated vaccines are expected to be available in the coming days, it said.While Spikevax is now approved in adults over 65 and in people aged 6 months through 64 years at high risk, mNEXSPIKE is approved for individuals 12 through 64 years of age at high risk and all adults over 65, the company said.While PFE stock is down by 6% this year, BNTX stock is down by 9%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/uk-regulator-approves-biogen-drug-for-treating-postnatal-depression/chsUel3Rdl9">UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Optimism has also been recently driven by Pfizer’s solid quarterly performance.

Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population

The agency approved the vaccine for use in adults aged 65 years and older, as well as in individuals aged 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

BMY Stock Trades Near 52-Week Low: Time to Buy or Sell? 

BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now. 

Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.

BioNTech is back in Wall Street’s spotlight after posting better-than-expected second-quarter results and doubling down on its cancer drug pipeline, prompting fresh price target upgrades from Clear Street and Bank of America.Clear Street lifted its price target to $185 from $181, highlighting BioNTech’s oncology pipeline and expected Phase 2 readouts for BNT327 in small cell lung and triple-negative breast cancer by the second half of 2025.&nbsp;Bank of America raised its target to $134 from $126, citing a top-line beat and continued execution in COVID-19 variant-adapted and combination vaccines.BioNTech’s collaboration with Bristol Myers Squibb (BMS) remains central to its oncology plans. The collaboration focuses on the development of BNT327, a PD-L1/VEGF-A bispecific antibody, and includes a $1.5 billion upfront payment expected in Q3.&nbsp;The deal could bring in up to $3.5 billion in non-contingent milestone payments through 2028, with another $7.6 billion tied to development and commercial milestones.For the second quarter ended June 30, BioNTech reported revenue of €260.8 million, more than double the €128.7 million it posted a year ago.&nbsp;The company recorded a net loss of €386.6 million, or €1.60 per share, a significant improvement from the €807.8 million loss, or €3.36 per share, in the same quarter last year.&nbsp;Cost controls also helped the bottom line, as R&amp;D expenses fell to €509 million, and SG&amp;A spending dropped to €137 million.BioNTech ended the quarter with a strong cash position of €16 billion, comprising cash, cash equivalents, and securities investments. The incoming $1.5 billion payment from BMS is expected to further boost liquidity in the third quarter.The company reaffirmed its 2025 revenue guidance of €1.7 billion to €2.2 billion, with the majority expected to be realized in the final months of the year. Full-year R&amp;D spending is projected between €2.6 billion and €2.8 billion, and SG&amp;A between €650 million and €750 million.On Stocktwits,&nbsp;<a href="https://stocktwits.com/symbol/BNTX">retail sentiment for BioNTech</a> was ‘extremely bullish’ amid ‘high’ message volume.BioNTech’s stock has declined 4.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Push

The German biotech firm reaffirmed its full-year guidance and reported lower operating expenses alongside a solid cash position. 

J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?

JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.

MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View

MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.

Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect

ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.

Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings 

PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.

Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View

BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales. 

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BNTX
BioNTech SE - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BNTX News

BNTX BioNTech SE - ADR